started · updated
CK Regeon to advance Phase 2 clinical trials for hair loss drug CKR-051
CK Regeon, a South Korean biotechnology company, has been selected for the Ministry of SMEs and Startups’ ‘Deep-Tech TIPS’ program. This selection provides the company with 2 billion won (including 1.5 billion won in government funds) to support the development of its hair loss drug candidate, CKR-051, over the next three years.
Following the completion of Phase 1 clinical trials in January 2024, which demonstrated safety and low systemic drug exposure, the company aims to transition the drug from an ointment to a liquid formulation. The goal is to complete non-clinical bridging studies and obtain approval for Phase 2 clinical trial plans (IND).
CKR-051 utilizes the company’s ‘WNT ON’ platform technology to target the WNT signaling pathway, which is essential for hair follicle formation and hair growth. Unlike existing treatments that suppress male hormones or increase blood flow, CKR-051 works by specifically interfering with the binding of the CXXC5 protein and the Dishevelled (Dvl) protein. This mechanism aims to restore suppressed WNT signaling and promote hair follicle cell regeneration.